SCHEMBL4173516

SCHEMBL4173516

N#Cc1ccc(NC(=O)C(O)(Cc2ccccc2-c2ccc(C(O)CO)cc2)c2ccccc2)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
AR P10275 14/20 0.43
RORC P51449 1/20 0.38
S1PR3 Q99500 1/20 0.38
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4170517 0.88 AR (0.46) ARGSK3AGSK3B
SCHEMBL13909428 0.88 AR (0.46) ARGSK3AGSK3B
SCHEMBL4180766 0.88 AR (0.46) ARGSK3AGSK3B
SCHEMBL4172613 0.87 AR (0.44) ARGSK3AGSK3B
SCHEMBL4167323 0.87 AR (0.47) AR
SCHEMBL4173554 0.86 AR (0.47) AR
SCHEMBL4170899 0.86 AR (0.48) ARGSK3AGSK3B
SCHEMBL4166868 0.85 AR (0.46) AR
SCHEMBL4178702 0.84 AR (0.47) AR
SCHEMBL4174583 0.82 GSK3A (0.47) ARGSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090075989-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS BAYER SCHERING PHARMA AG (DE) 2009-03-19 US disclosed
US-20090075989-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS BAYER SCHERING PHARMA AG (DE) 2009-03-19 US disclosed
US-20090075989-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS BAYER SCHERING PHARMA AG (DE) 2009-03-19 US disclosed
WO-2008077646-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090075989-A1 NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS NR5A1, CYP19A1, GPER1 AR 145/4885RORC 826/4885S1PR3 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.